3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
31
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Nasopharyngeal Carcinoma
36
Squamous Cell Carcinoma of Head and Neck
19
Head and Neck Neoplasms
17
Nasopharyngeal Neoplasms
7
Salivary Gland Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Esthesioneuroblastoma, Olfactory
3
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Hypopharyngeal Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Spinocerebellar Degenerations
1
Skin Neoplasms
1
Neoplasms, Unknown Primary
1
Interventions
pembrolizumab
9
Nivolumab
4
Magnetic Resonance Spectroscopy
3
spartalizumab
2
Ipilimumab
2
Gemcitabine
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Drug Therapy
2
Cisplatin
2
zenocutuzumab
1
venetoclax
1
ulixertinib
1
trametinib
1
tislelizumab
1
seribantumab
1
rovalpituzumab tesirine
1
pazopanib
1
neratinib
1
margetuximab
1
lenvatinib
1
entrectinib
1
durvalumab
1
cobimetinib
1
cemiplimab
1
budigalimab
1
bemarituzumab
1
atezolizumab
1
alectinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Capecitabine
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled